ImmunityBio (IBRX) stock rises before the bell after FDA talks point to new ANKTIVA filing
New York, Jan 22, 2026, 08:54 ET — Premarket ImmunityBio shares climbed in premarket trading Thursday following the company’s announcement that U.S. regulators have specified the requirements for a new filing to expand the use of its bladder cancer treatment.